{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:01:08Z","timestamp":1791352868231,"version":"4.3.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.bbr.2008.06.021","type":"journal-article","created":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T09:01:12Z","timestamp":1214643672000},"page":"44-51","source":"Crossref","is-referenced-by-count":24,"title":["Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism"],"prefix":"10.1016","volume":"194","author":[{"given":"Celia","family":"Larramendy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene R.E.","family":"Taravini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano D.","family":"Saborido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan E.","family":"Ferrario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario G.","family":"Murer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar S.","family":"Gershanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bbr.2008.06.021_bib1","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/mds.10589","article-title":"Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys","volume":"18","author":"B\u00e9langer","year":"2003","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.bbr.2008.06.021_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0022-510X(98)00307-4","article-title":"Pramipexole\u2014a new dopamine agonist for the treatment of Parkinson's disease","volume":"163","author":"Bennett","year":"1999","journal-title":"J Neurol Sci"},{"issue":"8","key":"10.1016\/j.bbr.2008.06.021_bib3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"10.1016\/j.bbr.2008.06.021_bib4","first-page":"275","article-title":"Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys","volume":"267","author":"Blanchet","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.bbr.2008.06.021_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00023210-200418110-00003","article-title":"The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled st&udy","volume":"18","author":"Bracco","year":"2004","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.bbr.2008.06.021_bib6","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nrn877","article-title":"Animal models of neurological deficits: how relevant is the rat?","volume":"3","author":"Cenci","year":"2002","journal-title":"Nat Rev Neurosci"},{"issue":"9","key":"10.1016\/j.bbr.2008.06.021_bib7","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/mds.21292","article-title":"Impact of pramipexole on the onset of levodopa-related dyskinesias","volume":"22","author":"Constantinescu","year":"2007","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.bbr.2008.06.021_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bbr.2003.10.009","article-title":"Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias","volume":"152","author":"Delfino","year":"2004","journal-title":"Behav Brain Res"},{"issue":"3","key":"10.1016\/j.bbr.2008.06.021_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mds.870110319","article-title":"High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias","volume":"11","author":"Facca","year":"1996","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.bbr.2008.06.021_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2165\/00003495-199855001-00002","article-title":"Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease","volume":"55","author":"Fariello","year":"1998","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bbr.2008.06.021_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0014-2999(90)94802-5","article-title":"Effect of chronic treatment of MPTP monkeys with dopamine D-1 and\/or D-2 receptor agonists","volume":"178","author":"Gagnon","year":"1990","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.bbr.2008.06.021_bib12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/0006-8993(96)00597-5","article-title":"Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates.","volume":"735","author":"Grondin","year":"1996","journal-title":"Brain Res"},{"issue":"4","key":"10.1016\/j.bbr.2008.06.021_bib13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00002826-200007000-00005","article-title":"Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys","volume":"23","author":"Hadj Tahar","year":"2000","journal-title":"Clin Neuropharmacol"},{"issue":"7","key":"10.1016\/j.bbr.2008.06.021_bib14","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archneur.61.7.1044","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial","volume":"61","author":"Holloway","year":"2004","journal-title":"Arch Neurol"},{"issue":"Pt 7","key":"10.1016\/j.bbr.2008.06.021_bib15","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/brain\/123.7.1365","article-title":"Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease.","volume":"123","author":"Lee","year":"2000","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.bbr.2008.06.021_bib16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.expneurol.2006.10.005","article-title":"Decreased expression of L-DOPA-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets","volume":"204","author":"Jackson","year":"2007","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.bbr.2008.06.021_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","author":"Lundblad","year":"2002","journal-title":"Eur J Neurosci"},{"issue":"5","key":"10.1016\/j.bbr.2008.06.021_bib18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ana.410310514","article-title":"Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys","volume":"31","author":"Luquin","year":"1992","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.bbr.2008.06.021_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/mds.1149","article-title":"Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)","volume":"16","author":"Maratos","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2008.06.021_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0014-2999(89)90296-3","article-title":"Time and dose dependence of the priming of the expression of dopamine receptor supersensitivity","volume":"162","author":"Morelli","year":"1989","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.bbr.2008.06.021_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.410270105","article-title":"Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease","volume":"27","author":"Mouradian","year":"1990","journal-title":"Ann Neurol"},{"issue":"suppl. 10","key":"10.1016\/j.bbr.2008.06.021_bib22","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/S1471-1931(00)00029-X","article-title":"Continuous dopamine-receptor stimulation in advanced Parkinson's disease","volume":"23","author":"Nutt","year":"2000","journal-title":"Trends Neurosci"},{"issue":"1","key":"10.1016\/j.bbr.2008.06.021_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mds.21060","article-title":"Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa?","volume":"22","author":"Nutt John","year":"2007","journal-title":"Mov Disord"},{"issue":"2 (Suppl 2)","key":"10.1016\/j.bbr.2008.06.021_bib24","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1212\/WNL.51.2_Suppl_2.S13","article-title":"Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease","volume":"51","author":"Ogawa","year":"1998","journal-title":"Neurology"},{"issue":"suppl. 10","key":"10.1016\/j.bbr.2008.06.021_bib25","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S1471-1931(00)00030-6","article-title":"Continuous dopamine-receptor stimulation in early Parkinson's disease","volume":"23","author":"Olanow","year":"2000","journal-title":"Trends Neurosci"},{"issue":"5 Pt 2","key":"10.1016\/j.bbr.2008.06.021_bib26","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1523\/JNEUROSCI.15-05-03863.1995","article-title":"Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test","volume":"15","author":"Olsson","year":"1995","journal-title":"J Neurosci"},{"issue":"7","key":"10.1016\/j.bbr.2008.06.021_bib27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","article-title":"Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Pahwa","year":"2006","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.bbr.2008.06.021_bib28","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group","volume":"284","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.bbr.2008.06.021_bib29","series-title":"The rat brain in stereotaxic co-ordinates","author":"Paxinos","year":"1986"},{"issue":"6","key":"10.1016\/j.bbr.2008.06.021_bib30","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.bbr.2008.06.021_bib31","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.870130207","article-title":"De novo administration of ropinirole and bromocriptine induces less dyskinesias than L-DOPA in the MPTP-treated marmoset","volume":"13","author":"Pearce","year":"1998","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.bbr.2008.06.021_bib32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0306-4522(96)00681-1","article-title":"Apomorphine priming alters the response of striatal outflow pathways to D2 agonist stimulation in 6-hydroxydopamine-lesioned rats","volume":"79","author":"Pollack","year":"1997","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.bbr.2008.06.021_bib33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/jnnp.42.2.143","article-title":"Long-term treatment of Parkinson's disease with bromocriptine","volume":"42","author":"Rascol","year":"1979","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"20","key":"10.1016\/j.bbr.2008.06.021_bib34","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa, 056 Study Group","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"issue":"Spec. no. 1","key":"10.1016\/j.bbr.2008.06.021_bib35","first-page":"S117","article-title":"Management of levodopa-induced dyskinesia","volume":"158","author":"Rascol","year":"2002","journal-title":"Rev Neurol (Paris)"},{"issue":"11","key":"10.1016\/j.bbr.2008.06.021_bib36","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/mds.20988","article-title":"Development of dyskinesias in a 5-year trial of ropinirole and L-DOPA","volume":"21","author":"Rascol","year":"2006","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.bbr.2008.06.021_bib37","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"issue":"2\/3","key":"10.1016\/j.bbr.2008.06.021_bib38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","article-title":"The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments","volume":"50","author":"Schwarting","year":"1996","journal-title":"Prog Neurobiol"},{"issue":"3","key":"10.1016\/j.bbr.2008.06.021_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0301-0082(96)00015-9","article-title":"Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae","volume":"49","author":"Schwarting","year":"1996","journal-title":"Prog Neurobiol"},{"issue":"2","key":"10.1016\/j.bbr.2008.06.021_bib40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.expneurol.2004.09.005","article-title":"Testing forelimb placing \u201cacross the midline\u201d reveals distinct, lesion-dependent patterns of recovery in rats","volume":"191","author":"Woodlee","year":"2005","journal-title":"Exp Neurol"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432808003227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432808003227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T11:08:45Z","timestamp":1557659325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432808003227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0166432808003227"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2008.06.021","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}